Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNCaP/IL-2/IFN-gamma Vaccine in Advanced Prostate Cancer
NCT00002637Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 1995
- Primary completion
- Feb 2001
- Modality
- Gene Editing, Gene Silencing, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of LNCaP + interleukin-2 + interferon-gamma in prostate cancer (PCa), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Safety of immunization and Post-therapy declines in PSA. Started Jan 1995; status: completed.
02
Drugs
LNCaP + interleukin-2 + interferon-gamma
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00002637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002637.